Home Biosimilar Antibodies Neuronal Signaling Beta Amyloid Bapineuzumab (Anti-Amyloid Beta)
For research use only. Not for use in humans.

Bapineuzumab (Anti-Amyloid Beta)

Synonyms: Abeta， A4

Bapineuzumab (Anti-Amyloid Beta) is a monoclonal antibody targeting β-amyloid protein (APP). It can be used for the research of Alzheimer’s disease (AD). MW :140.16 KD.

Bapineuzumab (Anti-Amyloid Beta)

Quality Control

Batch: A311101 Purity: 99% Protein concentration: 4.81mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation Beta Amyloid Others
DAPT 404 Notch
RO4929097 (RG-4733) 126 γ secretase,Notch
Semagacestat (LY450139) 22 Notch
MK-0752 23
Avagacestat (BMS-708163) 22
LY2811376 19 BACE1
CRANAD-2 0
Hoechst 34580 2
Frentizole 0
Simufilam 1
Ginsenoside Rg1 7 NF-κB
Ginsenoside Re 2 NF-κB,JNK
Tabersonine hydrochloride 2
EUK 134 8
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Bapineuzumab (Anti-Amyloid Beta) is a monoclonal antibody targeting β-amyloid protein (APP). It can be used for the research of Alzheimer’s disease (AD). MW :140.16 KD.
References

Product Details

CAS No. 648895-38-9
Isotype Human IgG1
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01254773 COMPLETED Drug: Experimental Bapineuzumab Alzheimer's Disease JANSSEN Alzheimer Immunotherapy Research & Development, LLC 2010-12 PHASE2
NCT00996918 TERMINATED Drug: Bapineuzumab 0.5 mg/kg|Drug: Bapineuzumab 1.0 m/kg Alzheimer Disease Pfizer 2009-12 PHASE3
NCT00667810 TERMINATED Drug: bapineuzumab|Drug: bapineuzumab|Drug: placebo Alzheimer Disease Pfizer 2008-06 PHASE3
NCT00676143 TERMINATED Drug: bapineuzumab|Drug: placebo Alzheimer Disease Pfizer 2008-01 PHASE3
NCT00998764 TERMINATED Drug: Bapineuzumab 0.5 mg/kg Alzheimer Disease Pfizer 2009-12 PHASE3
NCT00606476 TERMINATED Drug: Bapineuzumab (AAB-001) Alzheimer's Disease JANSSEN Alzheimer Immunotherapy Research & Development, LLC 2006-12 PHASE2

(data from https://clinicaltrials.gov, updated on 2014-05-09)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.